Advanced Search
Library
Infoposter

Nicotine pharmacokinetics and subjective effects following use of Platform 3

Full Title

Evaluation of nicotine pharmacokinetics and subjective effects following use of a novel nicotine aerosol system


Authored by  F Lüdicke, Murray Laugesen, Chris Wynne*, M Franzon, J Ancerewicz, Larissa Sandalic, Loyse Felber Medlin , P Brossard, A Teichert

Presented at GFN 2017    
* This author is not affiliated with PMI.

To learn more on the research and methods behind this poster, you’ll find a complementary brochure here - or view the poster and brochure together here.

PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts to develop and assess products that have the potential to reduce individual risk and population harm associated with tobacco use. This site is for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not for advertising or marketing. It is not intended for use by consumers.

Our RRPs

Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. Our RRPs are smoke-free products that produce an aerosol that contains far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.